Gastric cancer with metastases outside of the regional lymph nodes is deemed oncologically unresectable. Nevertheless, some metastatic lesions are technically resectable by applying established surgical techniques such as para-aortic lymphadenectomy and hepatectomy. At the time of compilation of the Japanese gastric cancer treatment guidelines version 4, systematic reviews were conducted to see whether it is feasible to make any recommendation to dissect both the primary and metastatic lesions with intent to cure, possibly as part of multimodality treatment.
Gastric adenocarcinoma has been feared as a particularly aggressive disease that has potential to spread through all of these pathways. 3 Lymph node metastasis is the only pattern of disease spread that occurs during the earlier stages so that surgery with adequate lymphadenectomy has been believed to confer not only precise staging but also prognostic benefit. 4 On the contrary, patients who harbor metastases to distant organs are considered to have little hope of cure even if the metastatic sites seem technically resectable, owing to rapid and almost inevitable growth of micrometastases that are likely to exist in such patients. This is in stark contrast with colorectal cancer in which hepatic and pulmonary metastases are often considered for surgery with intent to cure.
The present review attempts to identify situations where an aggressive surgical approach could be indicated for metastatic gastric cancer. There are two types of surgery for metastatic cancer. In one, the metastatic lesions are technically resectable, and a surgeon attempts complete resection of all lesions. The term "technically resectable" is ambiguous, may depend on the philosophy of each surgeon, and is extremely difficult to define. It may be more realistic to give the following as a typical example for each of the metastatic pathways: (i) cancer with a moderate number of swollen (≥1 cm) lymph nodes in the No. 16 a2/b1 regions which can be resected by the conventional technique of para-aortic lymph node dissection such as the one explored in a Japan Clinical Oncology Group (JCOG) randomized trial to be described later in this article; (ii) cancer with a small number of liver metastases (typically ≥3) of a size and location that can be dissected by hepatectomy without exceptional considerations; and (iii) cancer with a small number of peritoneal deposits which can be coresected easily at the time of gastrectomy. Patients usually undergo systemic chemotherapy, often in the form of neoadjuvant chemotherapy to eradicate micrometastases 5 and to avoid surgery in a cohort that suffers from rapid progression while chemotherapy is being given. In the other type, patients suffer from multiple metastases that are technically unresectable. Chemotherapy delivered to these patients sometimes results in complete or nearcomplete response of the metastatic lesion, which could render the primary lesion ± the remainders of the metastases resectable. This type of surgery has recently been referred to as conversion surgery.
Yoshida et al 6 have recently created a comprehensive classification of gastrectomy for stage IV cancer which takes into consideration the indications for both types of surgery.
| LYMPH NOD E METASTASIS
Before discussing metastases to various distant organs, it is necessary to discuss the value of lymph node dissection. Relevance of prophylactic lymph node dissection has been discussed thoroughly elsewhere, 7, 8 and various guidelines currently support standard application of D2 dissection to treat resectable advanced gastric cancer. 2, 9 However, cancer can spread beyond the boundary of standard D2 dissection. Thus, more extended lymphadenectomy had been proposed, but a campaign to enlarge the extent of prophylactic lymphadenectomy to include the para-aortic lymph nodes turned out to be a failure in the JCOG9501 trial, 10 a phase III trial in which the survival curve for the para-aortic lymph node dissection group overlapped completely with that for the D2 dissection group.
Patients with metastasis to the para-aortic lymph nodes are classified as stage IV. 11 This denotes that metastases to the para-aortic lymph nodes are considered as distant metastases. Para-aortic lymph nodes in the peritoneal cavity are classified anatomically as a1, a2, b1, and b2 ( Figure 1) . 11 During the 1980s, the technique for systematic dissection of a2/b1 lymph nodes was established and conducted experimentally in high-volume hospitals throughout Japan. The JCOG9501 trial was conducted based on these techniques, and para-aortic lymph node dissection was carried out safely with mortality and complication rates of 0.8% and 28.1%, respectively. One of the limitations of the trial was that the incidence of pathological para-aortic lymph node metastasis among patients allocated to extended lymphadenectomy was unexpectedly low at 8.5%. In fact, the trial did not include patients who had enlarged lymph nodes in the para-aortic region. Thus, survival benefit of para-aortic nodal dissection cannot be denied among patients who had apparently swollen lymph nodes in the para-aortic region. Sasako 12 proposed a neoadjuvant strategy to this patient cohort as they likely suffer from micrometastases and may benefit from tumor shrinkage. recently been referred to as conversion surgery. 6 Although this term has not been defined explicitly, it could be characterized as follows:
(i) surgery is not preplanned as in the case of neoadjuvant strategy, but is proposed after exceptional response of the metastatic lesions to chemotherapy; (ii) resection of all metastatic lesions that had originally been detected is not necessarily required, especially when complete response of such lesions was achieved; and (iii) surgery is indicated when information through imaging studies, laboratory data, and other modalities suggests possibility of R0 resection. There are sporadic reports of long-term survivors among the responders who underwent conversion surgery mainly for, but not restricted to, distant lymphatic metastases in retrospective analyses (Table 1) . [16] [17] [18] [19] Approximately 30% of patients who received chemotherapy underwent surgery. Series with higher incidence of R0 resection were associated with superior survival time. metastasis are single-institution case series consisting of 20-30 cases accumulated over more than two decades. 21 By systematically reviewing these reports, the Japanese Gastric Cancer Treatment
Guidelines committee came to a conclusion that a solitary nodule, lack of other non-curative factors, and favorable stage in terms of cT and cN categories of the primary tumor were among the factors that indicate better prognosis. 21 More recently, larger case series have been published through multi-institutional studies and combined analysis of data from highvolume hospitals ( Table 2 ) that reported a 5-year survival rate of approximately 30%. [22] [23] [24] Treatment selected in these studies was usually hepatectomy, but the amount of the liver resected varied widely depending not only on the number or size of the lesions but also on the preference of the surgeons. Two of these studies included radiofrequency ablation (RFA) as alternative treatment modalities. 22, 24 As the indication for RFA was limited based on the diameter and location of the metastatic tumors, it is currently impossible to see whether RFA could replace surgery. However, RFA did seem to show efficacy for a well-selected cohort of patients in these studies. Regardless of the details of treatment modalities selected, patients who were indicated for surgery in these studies usually had ≤3 nodules and, in one of the studies, a subset with a solitary nodule apparently had an outstanding outcome. 22 When discussing the number of metastatic nodules, the influence of the evolution of novel imaging modalities cannot be ignored as, again, most of the studies accrued patients over more than a decade. In this respect, one recent single-institution study was convincing because the authors looked only at patients with ≤3 nodules which were invariably diagnosed using enhanced magnetic resonance imaging (MRI).
The 5-year survival rate in that study also exceeded 30%. 25 Based on these studies, the Japanese guidelines decided not to deny the possibility of carrying out hepatectomy for those with a "small number" of metastatic nodules. 2 There are multi-institutional retrospective analyses from European countries, also showing that not all hepatectomies are futile. 26, 27 However, their conclusions tended to be reserved, indicating that a prospective study is needed to justify hepatectomy even in favorable situations. The only consensus between the east and the west is that some form of chemotherapy is needed prior to or after hepatectomy (or gastrectomy plus hepatectomy in cases of simultaneous metastasis) in order to eliminate the micrometastases that are likely to exist. When designing an international prospective trial to explore optimal multimodality treatment for "resectable" liver metastasis, however, the European investigators continue to show prudent attitudes and insist that a control arm to be treated by chemotherapy alone is necessary to confirm the prognostic impact of hepatectomy. 30 More recently, S-1 was found to significantly decrease the incidence of recurrence of peritoneal disease in a pivotal randomized trial comparing postoperative S-1 with surgery alone for stage II/III cancer. 39 Furthermore, in a one-arm study to explore efficacy of postoperative S-1 for patients with CY1/P0 or CY1/P1 status (here, P1 denotes a few deposits that could easily be coresected), the 5-year survival rate was 26%
| PERITONEAL METASTASIS
whereas there was no long-term survivor among the historical controls. 40 Thus, it was after the classification of S-1 that surgeons began to continue with gastrectomy for the CY1 population with some confidence. 41, 42 Accordingly, the current Japanese guidelines discuss the possibility of a multimodality treatment that includes gastrectomy for patients with CY1 cancer in the absence of other noncurative factors. 2 Nevertheless, when the CY1 status is diagnosed at the time of staging laparoscopy, surgery could be postponed and chemotherapy delivered as an initial treatment, so that only patients who responded and were converted to CY0 status at the second staging laparoscopy could be selected to proceed to gastrectomy. 37, 43 Treatments such as i.p. chemotherapy 44 and hyperthermic i.p. effusion chemotherapy (HIPEC) could add further impact, and some clinical trials exploring preoperative HIPEC by the laparoscopic approach 45 and HIPEC at the time of gastrectomy 46 have been conducted for the CY1 population.
Gastrectomy is far less likely to be conducted for patients with macroscopic peritoneal metastasis. Gastrectomy accompanied by total peritonectomy followed by HIPEC has been theoretically proposed as the ideal mode of treatment. 47, 48 Cytoreductive surgery and HIPEC remain to be widely explored for malignancies derived from the peritoneal mesothelioma, appendiceal mucinous neoplasms, and peritoneal metastases of colorectal and ovarian origin, 49 but several researchers decided not to further pursue this approach for gastric cancer because of uncertainty in efficacy despite the high morbidity. It is not practical to expect further exposure to anticancer agents after the classical combination of total peritonectomy followed by HIPEC because of serious adhesions.
However, benefits of i.p. administration of anticancer drugs in terms of pharmacokinetic advantages of higher intratumoral concentrations and less systemic toxicity remain attractive. Randomized trials that explored i.p. chemotherapy in various settings are listed in Table 3 . A single i.p. delivery of cisplatin on the day of surgery combined with further systemic chemotherapy did not confer any survival benefit over surgery alone when given in the postoperative adjuvant setting among serosa-positive CY0 patients. 50 Although this result was highly disappointing, repeated i.p. doses of paclitaxel in ovarian cancer 53, 54 aroused interest in the subsequent generation of
surgeons. An in vivo model of peritoneal dissemination implied efficacy of paclitaxel given i.p. compared with the same drug given i.v. 55 Pharmacokinetic study of paclitaxel delivered i.p. to patients with malignant ascites showed that the concentration of paclitaxel in the ascites was >2000-fold that of the plasma at 3 hours after the dosage. 38 Safety of i.p. dosage of paclitaxel, once questioned in cases of ovarian resection with colorectal coresection and anastomosis, 54 was confirmed in a trial in which i.p. paclitaxel was given immediately after gastrectomy. 56 However, survival benefit of a short series of i.p. doses of paclitaxel prior to the evidence-based systemic treatment was not proven for gastric cancer patients with risk factors for recurrence as peritoneal carcinomatosis (Table 3) . 51 This was considered attributable to the lack of systemic effect of single-agent chemotherapy because of the extremely poor transition of i.p. delivered paclitaxel to the plasma. 38 After some pilot studies, Ishigami et al 57, 58 conducted successive phase I and phase II trials to establish a combination of S-1, i.v. paclitaxel, and i.p. paclitaxel over S-1/cisplatin, the standard treatment, was suggested after adjusting for relevant prognostic factors. 52 Nevertheless, it is important to emphasize the need for R0 resection. Survival benefit of palliative resection prior to chemotherapy has been denied in a population of patients with unresectable distant metastases, including those with macroscopically evident peritoneal deposits. 59 Intraperitoneal chemotherapy could achieve complete response in some patients with peritoneal deposits so that initially unresectable patients could become candidates for R0 resec- These trials suggest importance of repeated exposure and combination with systemic chemotherapy. In the PHOENIX-GC trial, 52 patients were allocated in a 2:1 method.
Figures in parentheses denote 95% confidence interval.
IP, intraperitoneal chemotherapy; mo, months; MST, median survival time; OS, overall survival; PTX, paclitaxel.
greater detail compared with the previous version 2 ( Figure 2 ).
Queries regarding patients with minimal numbers of metastases in various metastatic categories are led to relevant clinical questions that are answered in the Q&A section of the guidelines by referring to the currently available evidence, as has been described in this review. 
| CONCLUSIONS

